Ross D. Camidge | Chemotherapy Targeted Therapy

Dr. Ross Camidge, a medical oncologist at the University of Colorado Cancer Center, comes with a very prestigious background, graduating from Oxford University. Dr. Camidge remained at Oxford for his fellowship, completed at the John Radcliffe Hospital. For the latter part of his career, Dr. Ross Camidge moved to the United States and started doing research in the field of thoracic malignancies, such as mesothelioma, with many articles and works published under his name. His studies in personalized treatment have helped advance the field in the last few years.

Oxford University Medical School, Oxford, UK - 1995

Medical School

John Radcliffe Hospital, Oxford, UK - 1995

Fellowship

American Board of Internal Medicine - Oncology

University of Colorado Cancer Center - Anschutz

Languages: English/Spanish

(720) 848-0300

1665 Aurora Ct

Aurora, Colorado 80045

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.

Kris MG, Camidge DR, Giaccone G, Hida T, Li BT, O\'Connell J, Taylor I,

Targeted therapy vs chemotherapy: which has had more impact on survival in lung cancer? Does targeted therapy make patients live longer? Hard to prove, but impossible to ignore.

Camidge DR. Clin Adv Hematol Oncol.

Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer.

Doebele RC1, Spigel D, Tehfe M, Thomas S, Reck M, Verma S, Eakle J, Bustin F, Goldschmidt J Jr, Cao D, Alexandris E, Yurasov S, Camidge DR, Bonomi P.

Acquired resistance to TKIs in solid tumours: learning from lung cancer.

Camidge DR, Pao W, Sequist LV. Nat Rev Clin Oncol.

Bio & Insurance Information

Dr. Ross Camidge, a medical oncologist at the University of Colorado Cancer Center, comes with a very prestigious background, graduating from Oxford University. Dr. Camidge remained at Oxford for his fellowship, completed at the John Radcliffe Hospital. For the latter part of his career, Dr. Ross Camidge moved to the United States and started doing research in the field of thoracic malignancies, such as mesothelioma, with many articles and works published under his name. His studies in personalized treatment have helped advance the field in the last few years.
Education & Training

Oxford University Medical School, Oxford, UK - 1995
Medical School
John Radcliffe Hospital, Oxford, UK - 1995
Fellowship
Board Certifications

American Board of Internal Medicine - Oncology
Hospital & Practice

University of Colorado Cancer Center - Anschutz

Languages: English/Spanish

(720) 848-0300

1665 Aurora Ct

Aurora, Colorado 80045
Read More
Publications & Memberships

Dr. Ross D. Camidge has contributed to 4 publications.

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.

Kris MG, Camidge DR, Giaccone G, Hida T, Li BT, O\'Connell J, Taylor I,
See more >>

Targeted therapy vs chemotherapy: which has had more impact on survival in lung cancer? Does targeted therapy make patients live longer? Hard to prove, but impossible to ignore.

Camidge DR. Clin Adv Hematol Oncol.
See more >>

Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer.

Doebele RC1, Spigel D, Tehfe M, Thomas S, Reck M, Verma S, Eakle J, Bustin F, Goldschmidt J Jr, Cao D, Alexandris E, Yurasov S, Camidge DR, Bonomi P.
See more >>

Acquired resistance to TKIs in solid tumours: learning from lung cancer.

Camidge DR, Pao W, Sequist LV. Nat Rev Clin Oncol.
See more >>

Request a call back

Request a call back

Dr. Ross D. Camidge has contributed to 4 publications.

Dr. Ross D. Camidge has contributed to 4 publications.